Tetraphase Pharmaceuticals (TTPH) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Tetraphase Pharmaceuticals (NASDAQ:TTPH) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02), Morningstar.com reports. Tetraphase Pharmaceuticals had a negative net margin of 421.64% and a negative return on equity of 67.34%. The company had revenue of $1.15 million during the quarter, compared to analyst estimates of $2.09 million.

NASDAQ:TTPH traded down $0.08 during trading hours on Friday, reaching $2.17. 808,354 shares of the company’s stock were exchanged, compared to its average volume of 678,728. The stock has a market cap of $118.93 million, a P/E ratio of -0.83 and a beta of 2.67. Tetraphase Pharmaceuticals has a 1-year low of $2.01 and a 1-year high of $6.97.

A number of large investors have recently modified their holdings of TTPH. Dimensional Fund Advisors LP boosted its stake in Tetraphase Pharmaceuticals by 28.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,832,741 shares of the biopharmaceutical company’s stock worth $5,627,000 after purchasing an additional 409,567 shares during the period. UBS Group AG acquired a new stake in Tetraphase Pharmaceuticals during the 1st quarter worth $1,130,000. Bank of New York Mellon Corp boosted its stake in Tetraphase Pharmaceuticals by 20.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 289,970 shares of the biopharmaceutical company’s stock worth $1,035,000 after purchasing an additional 49,332 shares during the period. Canada Pension Plan Investment Board acquired a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth $179,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in Tetraphase Pharmaceuticals by 9.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 275,630 shares of the biopharmaceutical company’s stock worth $984,000 after purchasing an additional 23,337 shares during the period. Hedge funds and other institutional investors own 41.02% of the company’s stock.

TTPH has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating on shares of Tetraphase Pharmaceuticals in a report on Monday, July 16th. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Thursday, August 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Friday, August 3rd. Finally, B. Riley increased their price target on shares of Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 28th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and an average target price of $6.16.

TRADEMARK VIOLATION WARNING: “Tetraphase Pharmaceuticals (TTPH) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2018/11/10/tetraphase-pharmaceuticals-ttph-releases-quarterly-earnings-results-misses-estimates-by-0-02-eps.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Article: Buyback For Investors Defined

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply